CorMedix Inc. CRMD Cash Flow

Cormedix inc. (CRMD)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss
-16,822	-16,433	-8,980	-13,951	-21,812	-26,829	-39,288	-39,008	-35,598	-33,009	-29,098	-28,268	-28,122	-24,643	-22,110	-17,672	-16,808	-18,187	-16,535	-16,882	-9,237	-20,453	-21,674	-19,139	-24,599	-9,133	-6,549	-5,066	-3,728	-3,380	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
2,306	2,439	2,005	1,794	1,546	1,110	1,486	1,540	1,580	1,659	1,678	1,456	1,457	1,335	1,237	1,966	2,528	3,225	3,134	2,380	1,779	2,168	2,533	2,689	2,778	1,345	844	551	159	274	0	0	0
Value of warrants issued in connection with backstop financing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-
Loss on foreign currency transactions
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	143	150	0	0	0	-	0	0	0	-	-	-	-
Stock issued in connection with license agreements
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Stock issued in connection with consulting agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Warrants issued in connection with license agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	76	0	0	0	-	-	-	-
Amortization of deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	282	341	242	158	76	0	0	0
Amortization of debt discount
-	313	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,054	1,310	1,162	607	279	0	0	0
Non-cash interest expense
-	461	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on issuance of preferred stock, convertible notes and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Non-cash charge for beneficial conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Inventory reserve
-	-	-	-	-	-	-	-	-	-	-	-	-	130	291	291	147	125	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss on issuance of warrants and preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Loss on modification of equity instruments and extinguishment of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,848	-9,258	-8,626	-14,045	-363	0	0	0	-	-	-	-
Expenses paid on behalf of the Company satisfied through the issuance of notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Depreciation
70	73	73	75	74	74	66	57	47	36	35	34	30	25	20	16	15	15	14	21	15	15	15	5	7	5	3	4	5	7	0	0	0
Changes in operating assets and liabilities:
Increase in trade receivables
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	171	171	131	-88	-220	-220	0	220	220	0	0	0	-	-	-	-
Decrease in trade receivables
-	-	-	-	-	-51	223	-146	-73	47	65	142	-259	-307	-103	-108	265	248	88	72	71	85	49	55	14	2	0	0	0	-	-	-	-
Decrease in inventory
-97	-59	42	-270	-159	-165	-85	219	157	100	-54	-67	-131	-79	-289	-266	19	38	196	612	572	558	406	278	63	80	0	0	0	-	-	-	-
(Increase) decrease in prepaid expenses and other current assets
3,304	67	-25	261	-166	-23	-795	-1,532	-278	-869	-392	-512	-1,737	505	1,379	1,929	2,248	645	270	96	13	-72	109	185	170	195	-56	-90	-100	-503	0	0	0
Security deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Increase (decrease) in accounts payable
-128	-1,564	-6,826	-6,399	-2,194	782	6,473	5,538	1,926	157	-352	656	147	-63	333	-33	148	825	717	327	436	8	-38	-439	-134	10	8	386	-168	-15	0	0	0
Decrease in accrued expenses
1,610	-363	-5,695	-1,645	-2,220	997	6,971	3,146	3,209	2,022	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	764	1,069	653	764	522	397	569	415	448	0	0	0	-	-	-	-
Accrued interest, related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Decrease in deferred revenue
-8	-8	-8	-7	-6	-76	-74	-90	-92	-25	-71	-56	-55	-52	114	114	114	113	-11	37	38	41	0	0	0	-	-	-	-	-	-	-	-
Accrued expenses and accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Deferred rent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-4	-4	-3	-2	-2	0	0	0
Net cash used in operating activities
-15,651	-15,052	-18,367	-19,513	-24,013	-23,700	-23,777	-25,467	-28,882	-28,587	-27,808	-27,557	-23,573	-22,265	-19,402	-15,797	-15,629	-12,526	-10,465	-9,332	-7,239	-6,320	-5,669	-5,376	-4,430	-3,618	-3,223	-2,376	-2,763	-2,276	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of short-term investments
9,938	14,106	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Maturity of short-term investments
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of short-term investments
-	-	-	-	-	1,604	6,796	14,683	20,028	23,583	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of equipment
27	36	27	33	29	48	174	186	188	151	30	60	60	58	56	3	2	15	13	19	38	25	61	55	35	35	0	0	0	0	0	0	0
Net cash provided by (used in) investing activities
-3,070	-12,020	-12,316	-11,850	-7,975	1,555	6,622	10,702	6,765	10,357	10,006	5,641	10,030	11,419	6,713	-3,212	-17,047	-23,608	-23,617	-13,402	-38	-25	-61	-55	-35	-35	0	0	0	0	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock from at-the-market program, net
2,469	15,234	26,189	33,052	33,933	21,968	16,208	9,345	8,464	5,543	356	4,566	6,427	6,229	7,429	6,479	28,601	28,451	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Repurchase of outstanding warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33	33	33	33	0	0	0	0
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0
Proceeds from notes payable to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	597	597	0	0	0
Proceeds from senior convertible note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	598	598	0	0	0
Repayment of amounts loaned under related party notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Proceeds from exchange agreement, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,723	6,723	7,223	7,223	1,033	0	0	0	-	-	-	0
Proceeds from senior convertible notes, related party, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from Series C-1 preferred stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from Series C-2 preferred stock, related party, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from Series C-3 preferred stock, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	743	743	743	743	0	0	0	0	-	-	-	-
Proceeds from Series C-3 preferred stock, related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	575	575	575	575	0	0	0	0	-	-	-	-
Proceeds from exercise of warrants
8,465	8,673	0	0	0	-	-	0	0	-	-	-	-	-	-	-	8,072	14,658	14,658	14,658	6,702	0	0	0	60	60	0	0	0	-	-	-	-
Proceeds from Galenica, Ltd. promissory note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Payments of financing fees
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	70	100	135	157	64	115	95	70	0	0	0
Proceeds from exercise of stock options
-	122	129	124	124	11	0	0	0	6	0	0	0	-	-	-	-	492	501	556	230	318	311	216	216	2	0	0	0	-	-	-	-
Net cash provided by financing activities
12,671	25,804	44,394	41,228	42,095	29,397	18,385	11,522	23,439	20,524	13,174	17,823	7,180	7,092	8,277	6,929	37,067	43,629	42,431	39,225	6,932	8,357	11,210	12,957	12,982	5,204	2,714	1,641	1,601	1,126	0	0	0
Foreign exchange effect on cash
-2	-2	-10	-4	-11	-7	1	6	20	19	11	8	-3	0	-8	-8	-5	-16	-20	-32	-44	-46	0	0	0	-	-	-	-	-	-	-	-
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS
-6,052	-1,270	13,699	9,859	10,094	7,244	1,231	-3,235	1,343	2,315	-4,614	-4,083	-6,366	-3,752	-4,420	-12,089	4,385	7,477	8,326	16,458	-390	1,965	5,436	7,493	8,496	1,538	-509	-735	-1,162	-1,149	0	0	0
Cash paid for interest
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental Disclosure of Non-Cash Financing Activities:
Issuance of common stock for payment of deferred fees
-	-	-	-	-	173	173	173	173	10	10	10	10	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of notes payable and accrued interest to common stock, fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,768	1,416	457	0	0	0	0	0
Exchange of convertible notes to preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Conversion of preferred stock to common stock
-	0	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,447	2,516	3,049	3,049	602	0	0	0	-	-	-	-
Unrealized loss from investments
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	1	4	7	7	5	3	0	0	1	2	3	4	3	3	2	2	2	26	62	91	118	93	56	26	0	0	0	0
Supplemental Disclosure of Non-Cash Financing and Investing Activities:
Unrealized loss from investments
-	-	-	-	-	-	-	-	0	-	0	0	0	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for vested restricted stock units
0	0	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for vested restricted stock units
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of derivative liabilities to equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Conversion of accounts payable and accrued expenses to preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Reclassification of derivative liability to equity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-
Conversion of wages and fees to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	50	104	141	115	96	0	0	0	-	-	-	-	-	-	-	-
Reclassification of deferred financing fees to additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Stock issued to technology finders and licensors
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Warrants issued to placement agent
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	106	106	0	0	0
Debt discount on senior convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,333	1,333	0	0	0
Dividends, including deemed dividends
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	0
Accrued and unpaid deferred financing cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0
Accrued private placement expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0